Hypertension is one of the leading independent risk factors for morbidity and mortality associated with cardiovascular disease (CVD). 1,2 Current hypertension management guidelines suggest reducing blood pressure (BP) to target levels via a combination of BP-lowering medications and lifestyle modifications. 3, 4 However, for a significant proportion of individuals, adequate BP control remains difficult to achieve, especially systolic BP (SBP). 5 Hypertension that remains uncontrolled despite optimized therapy with full doses of 3 antihypertensive agents (including a diuretic) is called treatment-resistant hypertension (TRH), 6 which has an estimated prevalence of 10%-30%. 7, 8 Patients suffering from TRH have 47% higher risk of having cardiovascular events compared with patients with controlled hypertension. 9 Catheter-based sympathetic renal denervation (RDN) represents a novel approach for the management of TRH that has been demonstrated to lower BP by up to 30 mm Hg in small-scale clinical trials. [10] [11] [12] However, the impact of RDN on significant BP reduction was not clarified in larger later-phase studies(i.e., SYMPLICITY HTN-3, PRAGUE-15), 13,14 which demonstrated a nonsignificant BP reduction of 0.5-2.4 mm Hg in the RDN group relative to control group when adjusted for baseline differences. However, the SYMPLICITY HTN-3 trial, a randomized blinded sham-controlled trial, demonstrated an effective BP reduction only in patients aged <65 years. 13 Furthermore, this reduction in BP relative to sham/control group was minimal (~6 mm Hg). These findings led to more refined patient selection for further ongoing clinical trials, which along with newer approaches for RDN, have shown early promise (i.e., registered clinical trials NCT01972139 and NCT01534299).
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RDN has been recognized as a cost-effective approach based on the findings of earlier clinical trials. 15, 16 However, there is lack of data on cost-effectiveness of RDN based on BP reduction from recent larger clinical trials, and also no information relevant to the Australian context. Hypertension is the greatest contributor to the CVD burden in Australia and one of the most common reasons for general practitioner consultations. 17, 18 Approximately one-third of the Australians aged 18 years and older have hypertension (systolic or diastolic BP is ≥140/90 mm Hg or taking medication) and of these, more than two-thirds have uncontrolled or unmanaged hypertension (not taking medication). 19 In light of recent findings regarding the minimal BP reduction with RDN compared with standard treatment observed only among patients aged <65 years, we sought to determine the cardiovascular risk thresholds at which RDN for TRH patients aged <65 years without initial CVD would be cost-effective, as well as the thresholds for the costs of RDN.
METHODS

Model structure
A Markov model was developed to simulate the onset of CVD and associated costs among a hypothetical cohort of 1,000 TRH patients without initial CVD. The health states for the model were "alive without CVD, " "alive with CVD, " "dead due to a CVD, " and "dead due to other causes" (Figure 1 ). CVD comprised myocardial infarction and/or stroke. All model subjects began the simulation in the health state "alive without CVD, " and in yearly cycles, could make transitions to the other health states, according to whether or not they developed nonfatal or fatal CVD, or died from other causes. In the base case analysis, a lifetime time horizon was adopted, meaning follow-up was simulated until subjects died or reached age 100 years. In sensitivity analyses, a 20-year time horizon was assumed.
Decision analysis 20 was used to compare outcomes among subjects assigned to standard treatment of care (SoC) and subjects assigned to RDN plus SoC. SoC was assumed to comprise the use of full doses of 3 antihypertensive agents (including a diuretic). Cost-effectiveness was evaluated from the Australian public health care system perspective.
Model inputs
Key input data for the model are summarized in Table 1 . The baseline cardiovascular risk among subjects in the SoC arm was varied to find the threshold at which RDN would be considered cost-effective from an Australian healthcare perspective. This constituted an incremental cost-effectiveness ratio (ICER) of Australian dollar (AUD) 50,000 per life year gained or per quality-adjusted life year (QALY) saved (as discussed below). For subjects in the RDN arm, baseline cardiovascular risk was reduced according to expected reductions in SBP over and above SoC (as discussed below). The extent of SBP reduction (5.7 mm Hg) was based on data from SYMPLICITY HTN-3 for participants aged <65 years. In both the SoC and RDN arms, cardiovascular risk was increased over time as would be expected from aging, and by the same extent in each arm. Age-related trends were based on those observed for cardiovascular mortality among the Australian population (Supplementary Table 1 ). 31 The proportional distribution of fatal and nonfatal CVD incident was based on data from the "Reduction of Atherothrombosis for Continued Health" registry, 32 while the proportional distribution of nonfatal incident myocardial infarctions and strokes were based on data from the Swedish Primary Care Cardiovascular Database 33 (Supplementary  Table 2 ). We assumed that the above proportions remained constant over the model time horizon. The "Reduction of Atherothrombosis for Continued Health" registry is a large data set (involving 67,888 subjects from 44 countries) designed to obtain information on CVD risk over long-term in patients with established CVD or without CVD but at high risk. 32 The Swedish Primary Care Cardiovascular Database comprises of 4,317 TRH patients (out of 74,751 hypertensive patients) aged ≥30 years without previous history of CVD and used to assess cardiovascular outcomes in these patients over a median 4.3 years compared with non-TRH patients. 33 Across different ages, the probabilities of dying from non-CVD (other) causes were obtained by subtracting probabilities for cardiovascular mortality from probabilities of all-cause mortality (Supplementary Table 1) 31 and assumed similar for both treatment arms. Following a primary CVD event, the risk of having fatal events was also estimated using data from the "Reduction of Atherothrombosis for Continued Health" registry, and it was assumed that the proportion of cardiovascular and other mortality remained the same for all subjects (Supplementary Table 2) . 32 At present, there is an absence of clinical trials comparing CVD endpoints in TRH patients treated with RDN compared with SoC. Therefore, expected changes to CVD risk from office BP reduction were based on data from a published metaregression. 21 For the effect of RDN on office BP reduction relative to SoC, SYMPLICITY HTN-3 data were used for participants aged <65 years. 13 Further, we assumed that SBP reduction due to RDN remained the same for all ages and was sustained over the model time horizon.
The utility (a measure of quality of life) assigned to the health state "alive without CVD" was assumed to be 0.98. 27 Utility values for the other health states were based on published sources (Table 1) . [28] [29] [30] Similarly, cost data for inpatient management of nonfatal (myocardial infarction, stroke) and fatal events, RDN, and antihypertensive medications were drawn from published sources (Table 1) . 22, 23, 25, 26 Costs for events and antihypertensive medication were converted to 2016-17 prices using the Total Health Price Index from the Australian Institute of Health and Welfare. 34 For antihypertensive medications, it was assumed that both the RDN and SoC arm used 3 antihypertensive drugs continuously. RDN cost was based on a micro-costing exercise undertaken by Medtronic Ltd., 24 and comprised the cost of catherization and material costs, including resources used for screening. The cost was applied as a one-off cost at the start of the first cycle of the RDN treatment arm.
Cost-effectiveness analyses
We conducted the cost-effectiveness analyses for a hypothetical cohort of 1,000 TRH patients and estimated subsequent events, life years gained, QALYs gained and costs for each year. An annual discount rate of 5% was applied to both costs and outcomes (years of life and QALYs), as recommended by Australian reimbursement authorities. 35 The ICER was calculated as the difference in cost divided by the difference in life years/QALYs between the treatment groups. There is no official willingness-to-pay threshold (the ICER which defines cost-effectiveness) that the Australian Government uses to fund and subsidize new drugs or treatments. However, several studies have quantified the relationship between ICERs and the probability of being listed for subsidy, 36, 37 and based on their findings, we used AUD 50,000 per life year or QALY gained as the willingness-to-pay threshold. a Fifty percent of the cardiovascular death cost was used as not all patients were hospitalized for fatal events from other cause.
Sensitivity analyses
In the base-case analysis, we assumed the effect of RDN on SBP reduction would be sustained over a life time. However, there is absence of clinical data on the persistence of RDNinduced BP lowering, and therefore, we conducted a sensitivity analysis whereby RDN was repeated every 10 years to maintain SBP reduction effect.
Further, one-way sensitivity analyses were conducted by altering the starting age, the RDN effect on BP reduction, utilities and the costs using uncertainty ranges listed in Table 1 . We increased/reduced the cost of complication management by 20% and also applied a 3% discount rate to future costs and benefits. The purpose of this was to assess the credible range for the ICER per life year or QALY gained for RDN compared with SoC.
Probabilistic sensitivity analyses were also undertaken via Monte Carlo simulation with 10,000 iterations. 38 This involves assuming uncertainty distributions for key input parameters and with each of the 10,000 simulations, sampling one value for each input parameter based on its uncertainty range. In probabilistic sensitivity analyses, relative risks and utility values were assumed to have beta distributions, SBP reduction was assumed to have a normal distribution, and costs were assumed to have gamma distributions (Table 1) . Results were presented using cost-effectiveness acceptability curves. Microsoft Excel (Microsoft Corporation, Redmond, WA) and @risk version 6.2 (Palisade Corporation, Ithaca, NY) were used for the economic analyses.
RESULTS
Base case analysis
In the base-case scenario over a lifetime horizon, among TRH patients initially aged 60 years, treatment with RDN plus SoC relative to SoC only was estimated to be cost-effective (≤AUD 50,000 per QALY saved) if their initial 10-year cardiovascular risk was at least 11.4%. However, cost-effectiveness in relation to both life year and QALY gained were achieved if the initial 10-year cardiovascular risk was at least 13.2% (Table 2) . With a 13.2% initial 10-year cardiovascular risk (~1.4% annual risk), the ICERs (discounted) were AUD 49,519 (~€34,151, 1€ = 1.45 AUD) per life year gained and AUD 47,130 (~€32,503) per QALY gained. The overall net cost (discounted) was AUD 8,697 per TRH patient with 0.18 life years or 0.19 QALY gained (discounted). Over a 20-year time horizon, cost-effectiveness in relation to both life years and QALYs gained were achieved if the initial annual cardiovascular risk was at least 24.3% (Table 2) .
Sensitivity analyses
If RDN is required to be repeated every 10 years to maintain treatment effect on BP reduction, cost-effectiveness in relation to both life years and QALYs gained was achieved if the initial 10-year cardiovascular risk was at least 61.1% ( Table 2 ). The results of one-way sensitivity analyses (based on uncertainty ranges listed in Table 1 ) showed that the ICERs were highly sensitive to BP lowering effect of RDN in relation to SoC. This was followed by the cost of RDN and the participant's age at RDN treatment. The results of the one-way sensitivity analyses are summarized in Figure 2 as tornado diagrams assuming a 13.2% initial 10-year cardiovascular risk. Using an annual discount rate of 3% instead of 5% led to ICERs of AUD 35,735 per life year gained and AUD 34,332 per QALY gained. If the costs of RDN were reduced to AUD 9,000, cost-effectiveness per life year gained would be achieved at an initial 10-year cardiovascular risk threshold of 10.9%. Reducing the RDN cost further to AUD 8,500 would achieve cost-effectiveness at 10-year cardiovascular risk thresholds of 9.1% (Table 3 ). In contrast, if the RDN cost increased to AUD 10,000, cost-effectiveness would be achieved at initial 10-year cardiovascular risk thresholds of 18.7%. Abbreviations: CVD, cardiovascular disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; RDN, renal denervation; SoC, standard treatment of care; TRH, treatment-resistant hypertension.
Probabilistic sensitivity analyses
The results of the probabilistic sensitivity analysis are shown as cost-effectiveness acceptability curves in Figure 3 . The 95% confidence interval for the ICER per life year gained ranged from AUD 32,629 to AUD 59,880 and for ICER per QALY gained ranged from AUD 31,354 to AUD 56,995. There was a 77% probability that the ICER for RDN would be less than AUD 50,000 per life year gained, and an 85% probability that it would be less than AUD 50,000 per QALY gained if the initial 10-year CVD risk was at least 13.2%. Scatter plots of incremental cost vs. incremental effectiveness are shown in Supplementary Figure 1 .
CONCLUSIONS
The results of our analyses indicate that using RDN in addition to SoC among TRH patients aged 60 years with an initial 10-year predicted cardiovascular disease risk of at least 13.2% would represent a cost-effective approach compared with SoC alone. The ICERs (discounted) for RDN were AUD 49,519 per life year gained and AUD 47,130 per QALY gained.
It is well established and biologically proven that RDN itself is effective and could safely reduce BP through decreasing the renal sympathetic tone. 39 Results from earlier published economic models of RDN compared with SoC also showed that RDN is a cost-effective approach at different cost-effectiveness threshold levels. 15, 16, 24, 40 However, none of these studies were conducted from the Australian health system perspective. Moreover, the effectiveness of RDN on BP reduction relative to SoC is not consistent among clinical trials, and the published economic models of these studies were based on findings from earlier clinical trials on RDN effectiveness, where RDN demonstrated an effective BP (statistically significant) reduction of up to 30 mm Hg compared with standard treatment. 11, 12, 16, 24, 40 To the best of our knowledge, this is the first study that uses "SYMPLICITY HTN-3" findings to evaluate cost-effectiveness based on RDN effect on BP reduction in relation to SoC.
"SYMPLICITY HTN-3" did not show a statistically significant BP lowering effect in participants undergoing RDN compared with those on standard treatment. However, among certain subgroups of study participants, RDN demonstrated a statistically significant reduction in BP, although the observed BP reduction was lower compared with earlier studies. In the present study, we tried to identify the group of TRH patients with an initial minimal absolute cardiovascular risk in whom the use of RDN would be cost-effective. Recently, post hoc analyses of "SYMPLICITY HTN-3" data indicated that poor adherence to medication as well as incomplete RDN might be the reason for observed nonsignificant BP reductions. 41 Therefore, addressing these issues might provide improved BP reduction. Recently, a randomized, sham-controlled, proof-of-concept trial reconfirmed the BP lowering efficacy of RDN. 39 These findings further strengthen our findings that use of RDN would be a cost-effective approach through effective BP reduction in TRH patients.
Further, earlier cost-effectiveness studies demonstrated that treating TRH patients' with RDN at a younger age (i.e., 50 years in relation to 70 years) would make RDN more cost-effective approach compared with standard treatment. 15, 24 This is possibly due to greater BP reduction in the younger age group for RDN and observed lower incidence of severe events compared with aged patients. A meta-analysis of BP lowering studies indicates that a 10 mm Hg lowering of SBP significantly reduces the risk of cardiovascular events. 21 Of course, RDN would also be more cost-effective if the cost of the procedure was reduced, and this is likely to occur as skills, experience, and technology improves (allowing for economies of scale), and competition increases.
There are limitations to our analysis that warrant mention. First, we used a surrogate measure for the effect of BP reduction on the reduction of CVD events. Although epidemiological studies demonstrate that BP reduction is associated with reduced long-term cardiovascular risk, 42 there remain no long-term follow-up data available from RDN trials that assess the effect of BP reduction by RDN compared with SoC on cardiovascular risk. Secondly, we assumed that all patients at the start of the model were "alive without CVD" to allow for less complex modeling. However, in the real world, the TRH population would also include people with existing CVD. Existing CVD portends a higher cardiovascular risk, and hence our model provided a conservative estimate of the cost-effectiveness of RDN for patients with TRH. Thirdly, we assumed that similar antihypertensive drugs were used in both the RDN and SoC arms. There is lack of information from RDN trials on number of antihypertensive drugs that were used, and if there were any changes to antihypertensive regimens. This information would be important for the cost-effective analysis, especially considering the price of the antihypertensive drugs that were used. Fourthly, RDN effect on BP reduction is dependent on the nature of RDN procedure. 43 Selecting and refinement of the RDN procedure based on patient condition might have a better impact on BP reduction and improved effectiveness of RDN. Our analysis was based on catheter-based RDN. Finally, we assumed that all subjects fully complied with medications. However, recently a meta-analysis showed that a large number of TRH patients do not comply with medications. 44 This also indicates that it is likely that RDN may be useful in patients who are noncompliant with medication.
In conclusion, at current costs and based on currently observed minimal effects on BP reduction, RDN is likely to be cost-effective in patients aged <65 years with an initial absolute 10-year predicted the cardiovascular risk of at least 13.2%. This level of risk would be common in patients with TRH. Our study sets the parameters for the future health 
